NASDAQ · BCTX
Healthcare · Biotechnology
$3.04
Down-$0.27 (-8.16%)
Updated Nov 2, 2026, 1:43 AM
SID Score
2.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · BCTX
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
BCTX closed at $3.04 after 20 trading sessions, down 27.27% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $3.35 | $3.35 | $2.95 | $3.04 | 130.85K |
| Oct 29, 2026 | $3.54 | $3.67 | $3.31 | $3.31 | 62.9K |
| Oct 28, 2026 | $3.54 | $3.64 | $3.46 | $3.50 | 43.27K |
| Oct 27, 2026 | $3.47 | $3.64 | $3.4522 | $3.56 | 49.88K |
| Oct 26, 2026 | $3.49 | $3.60 | $3.44 | $3.50 | 56.57K |
| Oct 23, 2026 | $3.47 | $3.64 | $3.3176 | $3.435 | 65.86K |
| Oct 22, 2026 | $3.64 | $3.67 | $3.40 | $3.41 | 61.71K |
| Oct 21, 2026 | $3.51 | $3.65 | $3.51 | $3.60 | 25K |
| Oct 20, 2026 | $3.36 | $3.59 | $3.36 | $3.46 | 35.79K |
| Oct 19, 2026 | $3.41 | $3.57 | $3.38 | $3.38 | 51.95K |
| Oct 16, 2026 | $3.70 | $3.9099 | $3.39 | $3.40 | 137.26K |
| Oct 15, 2026 | $3.71 | $3.8499 | $3.70 | $3.765 | 34.93K |
| Oct 14, 2026 | $3.70 | $3.881 | $3.67 | $3.69 | 50.59K |
| Oct 13, 2026 | $3.85 | $3.8728 | $3.71 | $3.71 | 54.22K |
| Oct 12, 2026 | $3.92 | $3.9476 | $3.86 | $3.87 | 24.77K |
| Oct 9, 2026 | $3.95 | $4.00 | $3.91 | $3.91 | 23.33K |
| Oct 8, 2026 | $4.0466 | $4.0466 | $3.87 | $3.92 | 48.7K |
| Oct 7, 2026 | $4.00 | $4.0999 | $3.91 | $4.00 | 84.51K |
| Oct 6, 2026 | $4.20 | $4.225 | $3.99 | $4.02 | 69.13K |
| Oct 5, 2026 | $4.04 | $4.22 | $3.9363 | $4.18 | 59.55K |
The latest Smart Investors Daily articles mentioning BCTX.
Company
Market Activity
Research & News
BCTX research
Company profile and research snapshot.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Sep 8, 2026
Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK)BriaCell Phase 3 trial featured in Nature Medicine as "Eleven clinical trials that will shape medicine in 2026" PHILADELPHIA and VANCOUVER,
Benzinga · Aug 24, 2026
Cell-based immunotherapy program is designed to harness patients’ own immune systemsBria-MEL+ is a personalized, off-the-shelf immunotherapy vaccine candidate intended to enable patient specific treatment without
Yahoo · Aug 5, 2026
FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a clinical study of Bria-PROS+ in prostate cancerBria-PROS+ is BriaCell’s next generation personalized immunotherapy for prostate cancer and incorporates additional immune activating components designed to enhance clinical efficacy Bria-PROS+ program previously awarded $2 million grant from the US National Cancer Institute PHILADELPHIA and VANCOUVER, British Columbia, Aug. 05, 2026 (GLOBE NEWSWIRE)
Benzinga · Aug 5, 2026
FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a clinical study of Bria-PROS+ in prostate cancerBria-PROS+ is BriaCell’s next generation personalized immunotherapy for
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BCTX.
